YM BioSciences’ highly selective JAK1/2 inhibitor, CYT387 has been granted Orphan Drug Designation. The drug is being developed for the potential treatment of myelofibrosis, a chronic debilitating disease in which a patient’s bone marrow is replaced by scar tissue, and for which treatment options are limited. The designation provides a seven-year period of U.S. marketing exclusivity upon approval as well as the ability to apply for annual grant funding, clinical research trial design as...